P21 (P021) Dosing: Studied Regimens (Preclinical)
> Updated:
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
P21 (P021) is a derivative of the active region of CNTF; it has been studied mainly preclinically (rodents, oral in feed), while research protocols usually administer it subcutaneously (less often intranasally). The below is a generalized reference from protocols, not a clinically validated regimen.
This is a concise reference to regimens described for adults; it is not an individual prescription.
P21 (P021) peptide searches are usually about the specific dose range rather than the mechanism of action, so the figures below collect those numbers from public sources without the status of a clinically validated schedule.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 100–250 mcg/day, subcutaneous | Starting dose |
| Typical regimen | 250–500 mcg/day, 4–6 week course | Increase if needed |
| Upper bound cited in protocols | up to ~1000 mcg/day | Maximum in this schedule |
Practical dosing details for P21
No controlled human clinical data exist for P21: only preclinical rodent studies and scattered protocols from public sources are available. So the schedule on this page (100–250 mcg to start, 250–500 mcg as the typical regimen, up to ~1000 mcg as the upper bound) is a summary of the ranges described in those sources, not the result of a controlled dose-finding trial.
Oral dosing in feed and subcutaneous injection are not interchangeable routes: peptides generally have lower oral bioavailability, so doses described for rodents on feed cannot be carried over directly to subcutaneous human-adjacent protocols without recalculating.
The gradual increase in these protocols follows the usual logic for a new research peptide: start at the lower bound, assess tolerability over a few weeks, and only then move to the upper range, rather than starting at the highest described dose.
This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.